Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.215 USD | -3.74% | -4.02% | +29.00% |
Sales 2024 * | 9.04M 6.57M | Sales 2025 * | 8.08M 5.87M | Capitalization | 863M 627M |
---|---|---|---|---|---|
Net income 2024 * | -99M -71.94M | Net income 2025 * | -105M -76.3M | EV / Sales 2024 * | 95.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 107 x |
P/E ratio 2024 * |
-8.56
x | P/E ratio 2025 * |
-8.52
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.71% |
Latest transcript on Arbutus Biopharma Corporation
1 day | -3.74% | ||
1 week | -4.02% | ||
Current month | -4.02% | ||
1 month | +13.56% | ||
3 months | +19.44% | ||
6 months | +55.05% | ||
Current year | +29.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 17-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 59 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% | ||
0.02% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 3.225 | -3.44% | 575 259 |
24-06-06 | 3.34 | -7.99% | 1,624,352 |
24-06-05 | 3.63 | +8.68% | 2,087,103 |
24-06-04 | 3.34 | -2.34% | 1,002,021 |
24-06-03 | 3.42 | +1.79% | 744,022 |
Delayed Quote Nasdaq, June 07, 2024 at 12:38 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.00% | 630M | |
+0.82% | 93.19B | |
-1.32% | 39.62B | |
-12.38% | 33.78B | |
+64.77% | 26.82B | |
-15.99% | 15.35B | |
-6.21% | 13.13B | |
-11.38% | 11.6B | |
-49.84% | 10.26B | |
+5.24% | 9.43B |
- Stock Market
- Equities
- ABUS Stock